Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

Viatris also gets first negotiation rights on other drugs in Idorsia’s pipeline. The agreement was announced just ahead of Viatris' fourth-quarter results, which revealed a 5% fall in revenues ...

Viatris has demonstrated confidence in its product pipeline by raising its New Product Launch (NPL) revenue guidance for 2024 to the higher end of the $500 million to $600 million range.

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

It stands out for its ability to maximize its product portfolio and generate value through its robust drug pipeline. Viatris ...

Viatris Inc. (VTRS), headquartered in Canonsburg, Pennsylvania, is a leading global healthcare company dedicated to empowering people worldwide to live healthier at every stage of life. With a ...

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as ...

Valued at a market cap of $14.8 billion, Viatris Inc. (VTRS) is a healthcare company that operates in four segments: developed markets, Greater China, JANZ, and emerging markets. Based in ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other stocks. Wall Street’s main indices all finished in the green territory on Wednesday ...

One company value investors might notice is Viatris (VTRS). VTRS is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. Value investors also love the P/S ratio, which is ...